• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nationwide population-based infection- and vaccine-induced SARS-CoV-2 antibody seroprevalence in Germany in autumn/winter 2021/2022 - ECDC

Mary Wilson

Well-known member
09/Jan/2025

https://doi.org/10.2807/1560-7917.ES.2025.30.1.2400037

Mercuri Elisabetta, Schmid Lorenz, Poethko-Müller Christina, Schlaud Martin, Kußmaul Cânâ, Ordonez-Cruickshank Ana, Haller Sebastian, Rexroth Ute, Hamouda Osamah, Schaade Lars, Wieler Lothar H, Gößwald Antje, Schaffrath Rosario Angelika , on behalf of the RKI-SOEP-2 Study Group.​


Background: The first Corona Monitoring Nationwide

(RKI-SOEP) study (October 2020−February 2021) found

a low pre-vaccine SARS-CoV-2 antibody seroprevalence

(2.1%) in the German adult population (≥ 18 years).


Aim: The objective of this second RKI-SOEP (RKI-

SOEP-2) study in November 2021−March 2022 was to

estimate the prevalence of SARS-CoV-2-specific anti-

spike and/or anti-nucleocapsid (anti-N) IgG antibodies

(combined seroprevalence), past infection based on

infection-induced seroprevalence (anti-N), and basic

immunisation (at least two antigen contacts through

vaccination or infection) in individuals aged ≥ 14 years.

We also aimed to estimate under-reporting of infec-

tions.

Methods: Dried blood-spot specimens from a

population-based sample embedded in a dynamic

cohort, the Socio-Economic Panel (SOEP), were sero-

logically analysed. Resulting serological data and self-

reports via a questionnaire from the same individuals

were used to estimate prevalences. Results: Combined

seroprevalence was 90.7% (95% CI: 89.7%–91.6%)

without correction and 94.6% (95% CI: 93.6%–95.7%)

with correction for sensitivity/specificity and anti-

body waning. While one in nine individuals had been

infected (11.3%; 95% CI: 9.1%–13.5%), nine in 10 had a

basic immunisation (90%; 95% CI: 88.9–90.9%), pri-

marily due to vaccination. Population-weighted esti-

mates differed by age, region, and socioeconomic

deprivation. The under-reporting factor was estimated

as 1.55 (95% CI: 1.3–1.8).

Conclusions: When the SARS-

CoV-2-Omicron wave was beginning, most people had

been vaccinated, infected, or both. Large-scale vacci-

nation, but not a high infection rate, was able to fill

the immunity gap, especially in ≥ 65 year-olds who are

known to be at higher risk of severe COVID-19. Our

data point towards the need for targeted socioeco-

nomically, demographically and regionally stratified

mitigation strategies, including measures to enhance

vaccine uptake.


https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.1.2400037
 
Last edited:
Back
Top Bottom